Want to join the conversation?
$ABBV said that the FDA accepted its NDA for a once-daily, fixed-dosed formulation of VIEKIRA PAK to treat GT1 HCV. The proposed dosing for the fixed-dose formulation is three oral tablets, taken once daily with a meal, with or without ribavirin. $ABBV anticipates regulatory action on the new formulation in 2016.
Still in yesterday’s $PZZA shock. I thought everyone had more pizza this football season!!
$TSLA stock downgraded to sell from hold by brokerage firm CFRA Research. However, the firm lifted the price target by $35 to $240.
$LB shares have plummeted after a disappointing quarter.